Hosted on MSN38m
Akero’s cirrhosis treatment shows promise in Phase IIb studyIn subjects with baseline and week 96 biopsies, 39% of those treated with a 50mg dosage experienced cirrhosis reversal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback